Amit Goyal, MD

DocwireNews

Coronary microvascular dysfunction (CMD) remains a significant cause of angina in patients with no obstructive coronary artery disease (ANOCA), with limited therapeutic options. Building on prior evidence from the double-blind and sham-controlled COSIRA trial, which demonstrated the efficacy of the coronary sinus (CS) reducer in improving angina and quality of life in patients with refractory angina secondary to obstructive CAD, Tryon et al. explored its potential role in CMD.
In this Phase II study, 30 patients with invasively diagnosed CMD and refractory angina (Canadian Cardiovascular Society [CCS] class III-IV) without obstructive epicardial coronary artery disease, despite optimal medical therapy, underwent CS reducer implantation. Microvascular function and clinical outcomes were evaluated at baseline and again at 120 days post-implantation. The primary endpoints were changes in coronary microvascular function, according to coronary flow reserve (CFR) with intracoronary adenosine ≤ 2.5—assessing endothelium-independent CM—and coronary blood flow (CBF) increase of ≤ 50% in response to acetylcholine —assessing endothelium-dependent CMD. Those with severe coronary vasospasm in response to acetylcholine were excluded.
This single-arm study revealed significant improvements in both coronary microvascular function and clinical outcomes with CS reducer implantation. Included patients had a mean age of 54.8 +/- 11 years and 66.7% were women. Device implantation was successful in 30 of 32 patients (94%) with procedural failure in 2 patients due to unsuitable coronary sinus anatomy. Two patients suffered coronary sinus perforation requiring pericardiocentesis, both occurring early in the center’s experience. There were no procedural deaths or myocardial infarctions. Patients with impaired CFR (n=19) exhibited a median increase from 2.1 to 2.7 (p=0.0011), while those with reduced CBF response (n=11) demonstrated a median increase from -11.0% to +11.5% (p=0.042). CCS angina class improved from a median of 4.0 to 2.0 (p&lt;0.001), with 76.7% of patients having at least 1 CCS angina class improvement. Quality of life scores on the Seattle Angina Questionnaire significantly increased across all domains (p&lt;0.006 for all). Curiously, changes in CFR or CBF did not correlate well with changes in symptoms across the study participants, which raises questions about the mechanism of benefit and contributions of a placebo effect, although the data was likely not powered to assess such correlations.
The results suggest that the CS reducer could effectively redistribute myocardial blood flow, addressing ischemia at the microvascular level. Its efficacy in CMD extends the clinical scope of this device, previously tested for refractory angina in obstructive CAD. The physiological benefits observed in both endothelium-dependent and independent CMD underline its broad therapeutic applicability across the range of CMD phenotypes. These findings support the potential for the CS reducer to become an important tool in the otherwise meager treatment armamentarium for CMD.
Ongoing studies, including the CORSIRA-II trial, aim to establish the long-term safety and efficacy of the CS reducer in patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribution of the left coronary artery and who are deemed unsuitable for revascularization. These efforts are expected to refine patient selection criteria and further validate its role in addressing the unmet therapeutic needs of both CMD causing ANOCA as well as obstructive epicardial coronary disease without revascularization options.
References
Tryon, D, Corban, M, Alkhouli, M. et al. Coronary Sinus Reducer Improves Angina, Quality of Life, and Coronary Flow Reserve in Microvascular Dysfunction. J Am Coll Cardiol Intv. 2024 Dec, 17 (24) 2893–2904. <a href="https://doi.org/10.1016/j.jcin.2024.09.018">https://doi.org/10.1016/j.jcin.2024.09.018</a>

Laura Litwin

Sublobar Resection Versus Lobectomy for Early-Stage NSCLC: Systematic Review Compares Outcomes

Non-Small Cell Lung Cancer

Emily Menendez

Sotorasib Plus Panitumumab Approved by FDA for KRAS G12C-Mutated mCRC

Colorectal Cancer

Jordana Jampel

New Drug for IBD Designed Using Generative AI

Gastroenterology

Latest News

Coronary Sinus Reducer Shows Promise for Coronary Microvascular Dysfunction

Cardionerds is an entertaining and educational medical cardiology podcast created by three cardiologists. They want to bring high yield cardiovascular concepts in a fun and engaging format for their listeners of all levels. Click below to learn more!

CardioNerds

Dr. Amit Goyal details a study which explored the role of coronary sinus reducer in Coronary microvascular dysfunction.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe